RxDoctor Payments Data

Andrew Glick, MD

Urology · Wilmington, DENPI 1356399935

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.2% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $215 and has fallen 57.0% since, to $93 in 2025. That places this record below the midpoint for urology clinicians in DE, where the typical reported total is $2,396.

$748in general payments, 2019–2025

Across 31 payments — averaging $24.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$97
  • Progenics Pharmaceuticals, Inc.$94
  • Merck$89
  • Palette Life Sciences, Inc.$84
  • Baxter Healthcare$60
  • Astellas Pharma US Inc$56
  • plus $268 from 10 others

What the payments were for

  • Food & beverage$68291%
  • Education$669%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$748 in reported general payments places this provider in the 25th percentile of 33 urology providers in Delaware.

See all urology providers in Delaware

Medicare billing

Part B allowed, 2024
$1,072,923
Medicare patients
1,498
Services billed
26,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide40$671,260
Abiraterone Acetate64$97,201
OrgovyxRelugolix29$82,447
GemtesaVibegron33$36,699
MyrbetriqMirabegron24$22,991
Tamsulosin Hcl949$17,843
Finasteride718$13,236
Potassium Citrate ErPotassium Citrate51$9,209
Cefpodoxime Proxetil172$1,931
Silodosin16$1,845
Oxybutynin Chloride ErOxybutynin Chloride34$1,220
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst98$839
Cephalexin312$753
Alfuzosin Hcl ErAlfuzosin Hcl17$691
Oxybutynin Chloride26$635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$56$694,25264 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 33 urology providers in Delaware.

Other urology in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →